Kezar Life Sciences Inc KZR
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
Is it the right time to buy, sell, or hold?
Start a free trial of Morningstar Investor to unlock exclusive ratings and continuous analyst coverage to help you decide if KZR is a good fit for your portfolio.
News
-
Kezar Announces Inducement Grant Under NASDAQ Listing Rule 5635(c)(4)
-
Kezar Life Sciences Reports Fourth Quarter and Year End 2023 Financial Results and Provides Business Update
-
Kezar Announces Inducement Grant Under NASDAQ Listing Rule 5635(c)(4)
-
Kezar Life Sciences to Participate in the TD Cowen 44th Annual Health Care Conference
-
Everest Medicines and Kezar Life Sciences Receive IND Approval from China NMPA for PALIZADE Trial in Lupus Nephritis
-
Stocks to Watch: FedEx, Kezar Life Sciences, Transcat
Trading Information
- Previous Close Price
- $0.79
- Day Range
- $0.78–0.80
- 52-Week Range
- $0.68–3.12
- Bid/Ask
- $0.79 / $0.79
- Market Cap
- $57.51 Mil
- Volume/Avg
- 233,506 / 796,101
Key Statistics
- Price/Earnings (Normalized)
- —
- Price/Sales
- 8.16
- Dividend Yield (Trailing)
- —
- Dividend Yield (Forward)
- —
- Total Yield
- —
Company Profile
Kezar Life Sciences Inc is a clinical-stage biotechnology company. It is engaged in discovering and developing novel small molecule therapeutics to treat unmet needs in autoimmunity and cancer. The pipeline consist of product candidates such as Zetomipzomib (KZR-616), and KZR-261.
- Sector
- Healthcare
- Industry
- Biotechnology
- Stock Style Box
- Small Value
- Total Number of Employees
- 58
Comparables
Valuation
|
Metric
|
KZR
|
VOR
|
SLRN
|
|---|---|---|---|
Price/Earnings (Normalized) | — | — | — |
Price/Book Value | 0.31 | 0.78 | 0.73 |
Price/Sales | 8.16 | — | — |
Price/Cash Flow | — | — | — |
Price/Earnings
No chart available
Financial Strength
|
Metric
|
KZR
|
VOR
|
SLRN
|
|---|---|---|---|
Quick Ratio | 11.35 | 8.81 | 8.53 |
Current Ratio | 11.66 | 9.04 | 8.65 |
Interest Coverage | −71.89 | — | — |
Quick Ratio
KZR
VOR
SLRN
Profitability
|
Metric
|
KZR
|
VOR
|
SLRN
|
|---|---|---|---|
Return on Assets (Normalized) | −30.67% | −41.83% | −57.50% |
Return on Equity (Normalized) | −34.89% | −51.69% | −88.66% |
Return on Invested Capital (Normalized) | −35.90% | −47.03% | −96.26% |
Return on Assets
KZR
VOR
SLRN
Biotechnology Industry Comparables
|
Ticker
|
Name
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|---|
NVO
| Novo Nordisk A/S ADR | Tyzghyxq | Gcpp | $550.4 Bil | |
VRTX
| Vertex Pharmaceuticals Inc | Gtkqpjvl | Xtssch | $101.7 Bil | |
REGN
| Regeneron Pharmaceuticals Inc | Zzgvjsdxz | Yhjghzh | $98.1 Bil | |
MRNA
| Moderna Inc | Tggkrrh | Ddt | $39.1 Bil | |
ARGX
| argenx SE ADR | Pphdfxjt | Yyydg | $21.7 Bil | |
BNTX
| BioNTech SE ADR | Ntzfvsjm | Xkcxt | $20.8 Bil | |
ALNY
| Alnylam Pharmaceuticals Inc | Lkznjtfyq | Znhycxm | $18.4 Bil | |
BMRN
| Biomarin Pharmaceutical Inc | Knyvknnx | Pwqxsw | $17.1 Bil | |
RPRX
| Royalty Pharma PLC Class A | Tqtntyvvgg | Zzqbrj | $12.5 Bil | |
INCY
| Incyte Corp | Mnwrxbt | Pqnlmb | $11.9 Bil |